Morgan J P, Funderburk F R
City University of New York Medical School, NY 10031.
Am J Clin Nutr. 1992 Jan;55(1 Suppl):206S-210S. doi: 10.1093/ajcn/55.1.206s.
The use of phenylpropanolamine (PPA) as an anorectic has provoked commentary and disagreement. Its use in the last decade has been associated with a series of adverse clinical events. As in all case reports, these associations may be noncausal, particularly in light of PPAs extensive use. We have reviewed prospective clinical trials in which the administration of PPA was planned to assess impact on blood pressure. Many of these employ sedentary, healthy volunteers but also included are studies of overweight, moderately hypertensive, and ambulatory subjects. An analysis of such studies leads us to believe that PPA is an appropriately marketed over-the-counter drug, with an acceptable margin of safety. Further, we have reanalyzed our own earlier published data, which indicate that the margin of safety may actually be increased in subjects with elevated basal sympathetic tone; eg, those who are overweight and those with slight elevations of arterial blood pressure.
使用苯丙醇胺（PPA）作为食欲抑制剂引发了诸多评论和争议。在过去十年中，其使用与一系列不良临床事件相关。如同所有病例报告一样，这些关联可能并非因果关系，尤其是考虑到PPA的广泛使用。我们回顾了前瞻性临床试验，这些试验计划使用PPA来评估其对血压的影响。其中许多试验采用久坐不动的健康志愿者，但也包括对超重、中度高血压和非卧床受试者的研究。对这些研究的分析使我们相信，PPA是一种销售得当的非处方药，具有可接受的安全范围。此外，我们重新分析了我们自己早期发表的数据，这些数据表明，在基础交感神经张力升高的受试者中，如超重者和动脉血压略有升高者，安全范围实际上可能会增加。
